Immune cell subset profiling and metabolic dysregulation define the divergent immune microenvironments in HIV immunological non-responders

Abstract

Background: A subset of people living with HIV (PLWH) exhibit poor immune recovery despite effective antiretroviral therapy (ART), remaining at risk of disease progression. The immunometabolic mechanisms underlying this immunological non-response remain unclear.

Methods: We integrated transcriptomic and immunophenotypic approaches to characterise immune differences between immunological responders (IRs) and non-responders (INRs). Public datasets were analysed to identify differentially expressed genes (DEGs), followed by enrichment analysis, predictive modelling, immune infiltration assessment, and regulatory network construction. In parallel, flow cytometry was performed to assess T and B cell subsets in an independent cohort including IRs, INRs, treatment-naïve patients (TNPs), and healthy controls (HCs).

Results: DEGs between IRs and INRs were enriched in mitochondrial and ribosomal pathways. INRs showed reduced Th1, Th17, and Tfh cells, alongside increased markers of immune activation and exhaustion. Predictive modelling identified five hub genes (ATP5O, PIGY, UQCRQ, COX7C, and BLVRB) associated with immune recovery, and clustering based on their expression defined two transcriptionally distinct subtypes. Flow cytometry further confirmed that INRs exhibited diminished CD4⁺ T cell counts, increased PD-1⁺ and HLA-DR⁺ expression, and reduced resting memory B cells, reflecting persistent immune dysfunction.

Conclusions: This study underscores the pivotal role of immunometabolic dysregulation in shaping heterogeneous immune responses to ART. By integrating computational and experimental data, we identified key biomarkers and regulatory pathways associated with immune recovery. Our findings highlight the central influence of metabolic processes on immune restoration outcomes and propose personalised metabolic interventions as a promising strategy to enhance therapeutic efficacy in HIV-infected individuals.

Keywords

acquired immunodeficiency syndrome / hub genes / immune cell infiltration / immunological non-responders / immunological responders / therapeutic targets

References

[1] French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009; 48(1): 101-107.

[2] Kazer SW, Walker BD, Shalek AK. Evolution and diversity of immune responses during acute HIV infection. Immunity. 2020; 53(5): 908-924.

[3] Guinan ME, Hardy A. Epidemiology of AIDS in women in the United States, 1981 through 1986. Jama. 1987; 257(15): 2039-2076.

[4] Nachega JB, Scarsi KK, Gandhi M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023; 10(5): e332-e42.

[5] Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278(5341): 1295-1300.

[6] Estes JD, LeGrand R, Petrovas C. Visualizing the immune system: providing key insights into HIV/SIV infections. Front Immunol. 2018; 9: 423.

[7] Baker JV, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr. 2008; 48(5): 541-546.

[8] Massanella M, Negredo E, Clotet B, et al. Immunodiscordant responses to HAART–mechanisms and consequences. Expert Rev Clin Immunol. 2013; 9(11): 1135-1149.

[9] Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007; 44(3): 441-446.

[10] García F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004; 36(2): 702-713.

[11] Zhang LX, Song JW, Zhang C, et al. Dynamics of HIV reservoir decay and naïve CD4 T-cell recovery between immune non-responders and complete responders on long-term antiretroviral treatment. Clin Immunol. 2021; 229: 108773.

[12] Yang X, Su B, Zhang X, et al. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: challenges of immunological non-responders. J Leukoc Biol. 2020; 107(4): 597-612.

[13] Guo FP, Li YJ, Qiu ZF, et al. Baseline naive CD4+ T-cell level predicting immune reconstitution in treated HIV-infected late presenters. Chin Med J (Engl). 2016; 129(22): 2683-2690.

[14] Ding Y, Pu C, Zhang X, et al. Identification of potential diagnostic genes of HIV-infected immunological non-responders on bioinformatics analysis. J Inflamm Res. 2023; 16: 1555-1570.

[15] Xiao Q, Han J, Yu F, et al. Elucidating the gene signatures and immune cell types in HIV-infected immunological non-responders by bioinformatics analyses. Int J Gen Med. 2022; 15: 8491-8507.

[16] Soria A, Guerini FR, Bandera A, et al. KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy. PLoS One. 2011; 6(11): e27349.

[17] Jensen BO, Knops E, Cords L, et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation. Nat Med. 2023; 29(3): 583-587.

[18] Joy MT, Ben Assayag E, Shabashov-Stone D, et al. CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury. Cell. 2019; 176(5): 1143-1157. e13.

[19] Carvalho-Silva WHV, Andrade-Santos JL, Guedes M, et al. CCR5 genotype and pre-treatment CD4+ T-cell count influence immunological recovery of HIV-positive patients during antiretroviral therapy. Gene. 2020; 741: 144568.

[20] Andrade-Santos JL, Carvalho-Silva WHV, Coelho AVC, et al. IL18 gene polymorphism and its influence on CD4+ T-cell recovery in HIV-positive patients receiving antiretroviral therapy. Infect Genet Evol. 2019; 75: 103997.

[21] Nguyen NV, Tran JT, Sanchez DJ. HIV blocks type I IFN signaling through disruption of STAT1 phosphorylation. Innate Immun. 2018; 24(8): 490-500.

[22] Mertowska P, Smolak K, Mertowski S, et al. Immunomodulatory role of interferons in viral and bacterial infections. Int J Mol Sci. 2023; 24(12).

[23] Younes SA, Talla A, Pereira Ribeiro S, et al. Cycling CD4+ T cells in HIV-infected immune nonresponders have mitochondrial dysfunction. J Clin Invest. 2018; 128(11): 5083-5094.

[24] Gong Y, Ji P, Yang YS, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021; 33(1): 51-64. e9.

[25] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43): 15545-15550.

[26] Cao J, Zhang C, Jiang GQ, et al. Identification of hepatocellular carcinoma-related genes associated with macrophage differentiation based on bioinformatics analyses. Bioengineered. 2021; 12(1): 296-309.

[27] Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12): 1572-1573.

[28] Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28(1): 27-30.

[29] Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019; 28(11): 1947-1951.

[30] Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol. 2018; 20(7): 745-754.

[31] Green R, Noller HF. Ribosomes and translation. Annu Rev Biochem. 1997; 66: 679-716.

[32] Clerc I, Moussa DA, Vahlas Z, et al. Entry of glucose- and glutamine-derived carbons into the citric acid cycle supports early steps of HIV-1 infection in CD4 T cells. Nat Metab. 2019; 1(7): 717-730.

[33] Edagwa B, McMillan J, Sillman B, et al. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017; 14(11): 1281-1291.

[34] Shete A, Dhayarkar S, Sangale S, et al. Incomplete functional T-cell reconstitution in immunological non-responders at one year after initiation of antiretroviral therapy possibly predisposes them to infectious diseases. Int J Infect Dis. 2019; 81: 114-122.

[35] Li H, Tang Y, Wang Y, et al. Single-cell sequencing resolves the landscape of immune cells and regulatory mechanisms in HIV-infected immune non-responders. Cell Death Dis. 2022; 13(10): 849.

[36] Lisco A, Wong CS, Lage SL, et al. Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression. JCI Insight. 2019; 4(8).

[37] Lorvik KB, Meyer-Myklestad MH, Kushekar K, et al. Enhanced gut-homing dynamics and pronounced exhaustion of mucosal and blood CD4(+) T cells in HIV-infected immunological non-responders. Front Immunol. 2021; 12: 744155.

[38] Vos W, Navas A, Meeder EMG, et al. HIV immunological non-responders are characterized by extensive immunosenescence and impaired lymphocyte cytokine production capacity. Front Immunol. 2024; 15: 1350065.

[39] Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012; 10(9): 655-666.

[40] Zhang W, Ruan L. Recent advances in poor HIV immune reconstitution: what will the future look like?. Front Microbiol. 2023; 14: 1236460.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.